Showing 6,014 results

Filters Content type: News, Editors' picks, About HIV Topic: HIV treatment

Treatment is recommended for all people living with HIV. It involves taking a combination of antiretroviral drugs. This stops the virus from replicating and allows the immune system to strengthen and fight infections.

Changing treatment

Reduced dose darunavir/ritonavir effective and safe for people switching while virally suppressed

News
30 July 2018
Treatment outcomes & life expectancy

Three-quarters of deaths of people with HIV in London are due to non-AIDS conditions

News
28 July 2018
The search for a cure

The kick that didn’t kill: first-ever randomised HIV cure study fails to eliminate infected cells

News
26 July 2018
Government, leadership & policy

Why are some countries slow to implement HIV treatment guidelines?

News
25 July 2018
Treatment simplification strategies

Dolutegravir dual therapy works well for first-time HIV treatment

News
25 July 2018
PrEP science

PrEP does not lower feminising hormone level in transgender women

News
25 July 2018
Treatment for women

Dolutegravir: update on infant neural tube defects from Botswana

News
24 July 2018
Treatment guidelines

Dolutegravir-based ART recommended for all – if reliable contraception is available

News
24 July 2018
Starting treatment

Brazil confirms dolutegravir is the most effective drug for first-line HIV treatment

News
24 July 2018
Undetectable viral load & treatment as prevention

Australian doctors to tell HIV patients that 'undetectable=untransmissible'

Editor's pick
Gay Star News
24 July 2018
New & experimental HIV treatments

The 2018 Pipeline Report

Editor's pick
TAG
24 July 2018
HIV treatment

Benefits, Risks of Dolutegravir Center Stage at AIDS 2018

Editor's pick
Medscape (requires free registration)
18 July 2018
New & experimental HIV treatments

FDA approves Janssen's HIV combination Symtuza

Editor's pick
Pharmaphorum
18 July 2018
Drug interactions & pharmacokinetics

Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1

Editor's pick
MHRA
18 July 2018
Pharmaceutical industry

Gilead's HIV Franchise Under Assault As It Stares Down Paradigm-Changing Drug

Editor's pick
Seeking Alpha
18 July 2018
Retention & linkage to care

TAC: ARV treatment education best way to bring down HIV infection rates

Editor's pick
Eyewitness News
18 July 2018
PrEP

Reported 'PrEP Failure' in Thailand May Be a Missed Acute HIV Infection: Here's What You Need to Know

Editor's pick
TheBody PRO
17 July 2018
New & experimental HIV treatments

CytoDyn Announces Positive Results from Completed Pivotal PRO 140 HIV Combination Trial

Editor's pick
CytoDyn press release
17 July 2018
Pregnancy and vertical transmission

Dolutegravir preconception signal: time is up for shoddy surveillance

Editor's pick
HIV i-Base
16 July 2018
Adherence

Blood, Hair, or Urine? Weighing PrEP Adherence Options Beyond Self-Report

Editor's pick
The Body Pro
16 July 2018
Side effects

We Must Talk About Having Diarrhea. I’ll Go First.

Editor's pick
My Fabulous Disease
16 July 2018
Pregnancy and vertical transmission

Dolutegravir: need to consider all pros and cons before switching in pregnancy

Editor's pick
HIV i-Base
11 July 2018
Changing treatment

Dolutegravir durable with high rates of viral suppression in people who experienced virological failure with older integrase inhibitors

News
9 July 2018
HIV treatment

Reduced-Dose Darunavir Effective in Virologically Suppressed HIV-1

Editor's pick
Infectious Disease Advisor
4 July 2018